Emerging LVAD Technology for the Use - Washington Hospital Center
Emerging LVAD Technology for the Use - Washington Hospital Center
Emerging LVAD Technology for the Use - Washington Hospital Center
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
• FDA approved<br />
Thoratec HeartMate II LVAS<br />
– Bridge to transplant – 2009<br />
– Destination Therapy – 2010<br />
• Clinical Experience<br />
– > 10,000 implants worldwide<br />
– Patients supported ≥ 3 years: 455<br />
– Patients supported ≥ 4 years: 158<br />
– Patients supported ≥ 5 years: 43<br />
– Patients supported ≥ 6 years: 14<br />
0<br />
– Patients supported ≥ 7 years: 2 Months<br />
Percent Survival<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
Implant dates n 30 d 6 Mo 12 mo<br />
a Apr ’08 - Oct ‘10 1496 95% 89% 85%<br />
b Apr ’08 - Aug ‘08 169 96% 90% 85%<br />
c Mar ’07 - Apr ‘08 205 95% 86% 80%<br />
d Mar ’05 - Mar ‘07 281 92% 82% 73%<br />
e Mar ’05 - May ’06 133 89% 75% 68%<br />
a John et al STS 2011<br />
b Starling et al JACC (in press)<br />
d Pagani et al JACC 2009<br />
e Miller et al NEJM 2007<br />
0 6 12<br />
Late Trial c<br />
Post-Trial a<br />
Post-Approval Study b<br />
Early-mid Trial d<br />
Early Trial e